• As Vertex Pharmaceuticals and Merck duel to introduce new drugs, ISI analyst Mark Schoenebaum has written that Bristol is among the companies that is closest to developing newer, more tolerable regimens.

    FORBES: Who's Better, Bristol-Myers or Novo Nordisk?

  • Over the past several days, there has been a great deal of confusion about the extent to which physicians are embracing the new Incivek hepatitis C drug that is sold by Vertex Pharmaceuticals.

    FORBES: The Hepatitis C Wars: What Docs Say About The Newest Meds

  • If you want to know why drug research remains a slow and frustrating business even in this golden age of molecular biology, look at the troubles Vertex Pharmaceuticals has gone through to devise a new drug to combat hepatitis C.

    FORBES: Magazine Article

  • His claims rely on a radical new approach to crafting drugs and, if it works, Vertex (nasdaq: VRTX - news - people ) may create a cornucopia of medicines to fight cancer, diabetes and other ailments faster and more cheaply than ever before.

    FORBES: Machine Gunner

  • Vertex also is in late-stage tests of a new AIDS drug, a protease inhibitor that requires only two pills a day versus six or more for rival remedies.

    FORBES: Machine Gunner

  • In the heated race to develop new hepatitis C drugs that boost the cure rate, Wall Street thinks Vertex Pharmaceuticals has a slightly better drug than a rival entry from Merck, and thus will garner the large majority of sales.

    FORBES: Why Aren't There AIDS-Style Cocktails for Hepatitis C?

  • Vertex Pharmaceuticals still is leading in the race to develop the first of a new generation of drugs for the deadly liver disease hepatitis C.

    FORBES: Vertex's Lead Narrows

  • With a study released this morning, Vertex Pharmaceuticals cemented a key advantage in what is expected to be a booming new market for hepatitis C drugs this morning, increasing its edge over Merck, its main competitor.

    FORBES: Vertex's Big Advantage

  • Vertex has a drug in the pipeline called telaprevir that it hopes will be the first in a new, more powerful generation of hep C treatments.

    FORBES: Magazine Article

  • Not all of these new drugs came from big pharma as biotech companies like Regeneron (Eylea for wet acute macular degeneration), Vertex (Kalydeco for cystic fibrosis) and Incyte (Jakafi for bone marrow disease) had major drugs approved.

    FORBES: Marcia Angell's Attacks on Pharma Have Lost all Credibility

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定